HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology. The study, which included 239 participants at 39 leading MS centers in the U.S. and Canada, demonstrated that a significantly greater proportion of people with MS taking dalfampridine extended release tablets had a consistent improvement in walking speed compared to those receiving placebo tablets (42.9 percent vs. 9.3 percent; p < 0.0001). These results were consistent with data from the first pivotal Phase 3 clinical trial, which were published in the February 29, 2009 edition of The Lancet.
